Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNAâ˘) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address oncology, inflammatory diseases and genetic disorders. Source
No articles found.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by si...
Arrowhead Pharmaceuticals develops medicines th...
Agios is a biopharmaceutical company passionately committed to applying our scient...
Agios is a biopharmaceutical company passionate...
Galmed is a clinical-stage biopharmaceutical company focused on the development of...
Galmed is a clinical-stage biopharmaceutical co...
We are Anchiano Therapeutics, a pivotal-stage biopharmaceutical company focused on...
We are Anchiano Therapeutics, a pivotal-stage b...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Anavex utilizes precision genetic medicine to treat severe and devastating neurolo...
Anavex utilizes precision genetic medicine to t...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...
Adaptimmune is a leader in TCR T-cell therapy, ...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company develop...
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stag...
Join the National Investor Network and get the latest information with your interests in mind.